Kornimate/medical-research-clean huggingface dataset:
insulin modelling based on plasma glucose measures via a minimally-invasive glucose sensor

Conditions: PreDiabetes

Summary: the study aims to evaluate insulin as a potential biomarker for prediabetes in singapore chinese subjects.

the prevalence of type 2 diabetes (t2dm) in singapore is expected to increase from 400,000 to 1,000,000 individuals by 2050, resulting in nearly us$2 billion in economic costs. pre-diabetes is defined as an intermediate state of hyperglycemia where blood glucose levels are elevated but are below the diagnostic levels of diabetes. in singapore, approximately 1 in 7, or 430,000 residents are estimated to be pre-diabetic, and globally this number is estimated at 7.3% of adults (equivalent to 352.1 million individuals). up to 70% of pre-diabetics eventually develop overt t2dm; however, pre-diabetes may be reversible with early detection, providing a window for opportune disease interception. while blood glucose is currently used to detect pre-diabetes, homeostatic mechanisms can maintain normal blood glucose levels and mask the detection of pre-diabetes until overt hyperglycemia is exhibited. in contrast, numerous studies have demonstrated that insulin levels increase markedly in pre-diabetes, even as marginal changes are observed in glucose levels. in this study, the investigator aims to determine if dynamic insulin levels observed during an oral glucose tolerance test are more sensitive than glucose alone in detecting prediabetes in a singapore chinese population.

Eligibility criteria:
inclusion criteria: * aged 21-60 * chinese ethnicity * male or female * adequate fluency in the english language to understand the informed consent process, study instructions and study assessments. * sufficient vision and hearing to complete the study procedures * willing and able to participate and to give written informed consent exclusion criteria: * diabetes diagnosis based on hba1c ≥ 6.5%, and fasting plasma glucose ≥ 7.0 mmol/l * past (\<3 months prior to the study) or current major metabolic, endocrine, gastrointestinal or cardiovascular disease * individuals diagnosed with non-alcoholic fatty liver disease * women diagnosed with polycystic ovary syndrome * major surgery in the past 2 months * past (\<1 month prior to the study) or current use of prescription, over the counter or traditional medication that may influence metabolic or gastrointestinal functioning * presence or past history of alcohol or drug addiction * smoking * pregnant or lactating * alcohol intake \>1 units per day * body mass index \<18.5 kg/m2 or ≥30 kg/m2 * member of the research team or their immediate family members
chlorobutanol, potassium carbonate, and irrigation in cerumen removal

Conditions: Ear Infection; Hearing Loss; Vertigo

Summary: accumulation of cerumen in the external ear canal is a common problem. the presence of cerumen not only interferes with the clinician's view of the tympanic membrane, but may also result in hearing loss and vertigo, and may predispose to ear infections. removal of cerumen is facilitated by the use of a variety of ceruminolytics, or wax solvents. the current study was designed to evaluate the ceruminolytic effects of a single, brief application of the two most frequently used products in the investigators area, containing chlorobutanol or potassium carbonate with or without irrigation in the primary care setting in a randomized, single-blind trial. to our knowledge, this is the first randomized study comparing ceruminolytics with chlorobutanol versus potassium carbonate.

interventions: subjects were randomly assigned to one of three different treatments: otocerum®; taponoto ®, and a control group with sterile saline solution (nacl 0.9%, braun medical sa, barcelona, spain). the test medication was instilled into an occluded ear for 15 minutes. following this treatment, the subject's ear was irrigated with 50 ml of water. the main outcome was the proportion of tympanic membranes that were completely visualized after cerumenolytic agents or saline, alone or with irrigation if needed.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ear cerumen exclusion criteria: * infection

Keywords: complete occlusion of the ear canal due to cerumen
mouthwashes during orthodontic treatment

Conditions: Gingivitis

Summary: the number of orthodontic treatment provided to brazilian population has been increased. unfortunately, some negative effects such as gum bleeding and bad breath are commonly observed. it partially happens because tooth brushing and flossing become more difficult in the presence of braces. therefore, there is a need for clinical protocols able to maintain the mouth healthy during orthodontic treatment. considering that proper use of mouthwashes by in individuals without braces is accompanied by decrease in plaque and gum inflammation levels, it was hypothesized that, during orthodontic treatment their anti-gingivitis and anti-plaque properties would positively affect oral health. objectives: the present study will compare the effects of two commercially available mouthwashes with a placebo mouthwash in orthodontic patients wearing fixed appliances. whole-mouth clinical examinations will be performed in periodontally healthy patients 15 days before, at the day of bonding and also 3 and 6 months after braces bonding. hard and soft tissues status, presence of gingivitis and amount of dental plaque will be monitored to determine mouthwashes efficacy. at these same time-points plaque samples will be collected from dental sites and braces surfaces aiming at determining total levels of bacteria and levels of specific bacteria related to gum disease. after a full-mouth ultrasonic debridement to remove dental plaque, stains and tartar, patients will be randomly assigned to an essential oils, cetylpyridinium chloride or a placebo mouthwash for 6 months (40 ml/day). further, samples of orthodontic wires will be analyzed under microscopy to check whether regular use of mouthwashes increases the risk of corrosion or not.


Eligibility criteria:
inclusion criteria: * good general health; * class i or class ii malocclusions with a nonsurgical orthodontic treatment plan for alignment and leveling including no-extraction, extraction of two upper premolars or extraction of four premolars; no previous orthodontic treatment; overbite and overjet that allowed brackets to be placed on the lower teeth without occlusal interferences; * periodontal health (with no clinical signals of inflammation, gi \<1 e no clinical attachment loss); * at least 26 natural teeth; exclusion criteria: * severe skeletal malocclusion in anteroposterior, vertical or transverse dimensions; surgical orthodontic plan; * mouth breathing; * gingivitis; periodontitis; gingival overgrowth; * prosthetic fixed devices, removable partial dentures or overhanging restorations; * systemic diseases or conditions that could influence the periodontal status; * smokers and former-smokers; * pregnancy or breast-feeding; * history of sensitivity or suspected allergies following the use of oral hygiene products; any antibiotic prophylaxis; * antibiotics and/or anti-inflammatory drug use in the six months prior to the beginning of the study; * regular use of chemotherapeutic antiplaque/antigingivitis products; * periodontal treatment performed within six months prior to study initiation; * unwillingness to return for follow-up.
bai-bace for advanced lung squamous cell carcinoma

Conditions: Squamous Cell Carcinoma

Summary: bronchial arterial infusion plus bronchial arterial chemoembolization (bai-bace) has been reported as non-first-line therapy to treat lung cancer in many hospitals in china. bai, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. then bace could seal off the tumor vessels. in this study, we aim to describe the efficacy and safety of bai-bace as non-first-line for advanced lung squamous cell carcinoma.

this study is a multicenter, interventional study to explore the efficacy, safety of bai-bace as non-first-line therapy for advanced central squamous cell carcinoma. lung cancer is the leading cause of cancer-related death worldwide. owing to the insidious symptom, most patients (about 75 %) are diagnosed at the advanced stage of the disease and, thus, cannot undergo resection. the central squamous cell carcinoma accounts for 25% of all cases of lung cancer. the first-line standard treatment for advanced central squamous cell carcinoma is combined chemoradiotherapy, and chemoradiotherapy is usually as the second-line. however, treatment failure is noted in many patients, and those patients often face the limited therapy choice and poor prognosis. bronchial arterial infusion plus bronchial arterial chemoembolization (bai-bace) has been reported to treat lung cancer in many hospitals in china. bai, which use chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. then bace could seal off the tumor vessels. the systemic toxicity of this surgery is low and tolerable. this study will provide clinical evidence that bace-bai will provide survival benefit for patients with advanced central squamous cell carcinoma.

Eligibility criteria:
inclusion criteria: 1. squamous cell carcinoma diagnosed by pathology, and central location by imaging; 2. age 18-80; 3. patients failed to the standard first-line or second-line treatment; 4. tumors limited in the chest; 5. tumors were fed by bronchial artery through cta reconstruction; 6. patents received pd-1 inhibitor or not were also included; 7. eastern cooperative oncology group performance status (ecog ps) of 0-2; 8. images within 2 weeks before inclusion; 9. life expectancy more than 3 months; 10. agreed to participated in this clinical trial; 11. hemameba ≥3.0 x109/l, neutrophil ≥1.5x109/l, hemoglobin≥10.0 g/l, platelet≥100x 109/l, alt; ast; bilirubin ≤1.5-fold normal, gfr≥60ml/min. exclusion criteria: 1. contraindication of bai or bace; 2. under 18 years or over 75 years; 3. extra-chest metastases; 4. receiving other antitumor treatment; 5. severe infection or pregnancy; 6. severe pulmonary fibrosis and pulmonary artery; 7. liver, kidney or poor physical conditions; 8. severe pleural effusion or pericardial effusion; 9. life expectancy less than 3 months.

Keywords: bronchial arterial infusion bronchial arterial chemoembolization paclitaxel callispheres cis-platinum advanced central squamous cell carcinoma
postoperative pain evaluation of mineral trioxide aggregate and propolis after pulpotomy in carious primary molars

Conditions: Pulp Disease, Dental

Summary: the study will be self-funded by investigator and carried out on patients from outpatient clinic in pediatric dentistry and public health department- faculty of dentistry, cairo university- egypt. the procedures will be carried out by postgraduate student rawda nader fathy who has b.d.s. (2011) -alexandria university- egypt. the procedures will be carried out on a knight midmark biltmore dental unit (midmark corporation 1700 s. patterson blvd. suite 400 dayton, ohio 45409, usa) in the post graduate clinic of pediatric dentistry and public health department- faculty of dentistry, cairo university- egypt.


Eligibility criteria:
inclusion criteria: 1. cooperative patient 2. healthy 5-8 years old patient with at least one carious primary molar tooth at each side of the patient's mouth. 3. presence of at least two-thirds of the root length radiographically. 4. restorable tooth. 5. no signs of hyperemia and hemostasis will be adequately achieved with moistened cotton pellet within 5 minutes after coronal pulp amputation. exclusion criteria: 1. teeth showing clinical and radiographic evidence of pulp degeneration such as history of spontaneous or nocturnal pain, tenderness to percussion or palpation, pathologic mobility, swelling or fistulous tract, periodontal ligament (pdl) space widening, internal root resorption, external root resorption, furcal radiolucency/inter- radicular bone destruction and/or periapical bone destruction. 2. patients eliciting history of known allergy to pollens associated with propolis. 3. parent or guardian refusal to participate.

Keywords: pulpotomy primary molars propolis
effect of covid-19 epidemic on primary pci in patients with stemi

Conditions: STEMI

Summary: the epidemic of covid-19 has spread all over the world and has a great impact on people's health and life. it is necessary to study the treatment of stemi patients in the real world under the influence of the epidemic,which provide effective suggestions and strategies for emergency and severe treatment.

the epidemic of covid-19 has spread all over the world and has a great impact on people's health and life. the patients' prognosis is poor because the epidemic situation runs on medical resources, delays the diagnosis and treatment of other diseases such as cardiovascular diseases, and the patients' willingness to see a doctor is reduced. in particular, the delay in the treatment of stemi, which needs pci treatment, will cause more damage to the patients. it is necessary to study the treatment of stemi patients in the real world under the influence of the epidemic. in this study, stemi patients who experienced emergency pci treatment after the covid-19 outbreak in 2020 were included, and compared with the data of the same period in 2019,we will analyze the pre hospital treatment time, vascular opening time,and the major cardiovascular adverse events, which provide effective suggestions and strategies for emergency and severe treatment.

Eligibility criteria:
inclusion criteria: * continuous inclusion of patients with definite diagnosis of acute st segment elevation myocardial infarction and emergency pci intervention. exclusion criteria: * febrile patients, patients with severe infection, * st segment elevation myocardial infarction during hospitalization, * patients who could not cooperate with each other.

Keywords: covid-19 stemi primary pci
replacement of saturated fat in dairy on total cholesterol

Conditions: Hypercholesterolemia

Summary: the consumption of milk and dairy products is recognised as an essential part of a healthy diet as it represents an important source of key micro- and macronutrients. nevertheless, there is still a widespread conviction that the overall high energy density and concentration of long-chain saturated fatty acids (sfa) present in dairy have detrimental health effects, contributing to the progression of cardiovascular disease, obesity and diabetes. supplementation of the bovine diet with a source of mufa, such as rapesee oil, has become an achievable strategy in order to reduce the amount of sfa present in dairy products. the aim of this project is to observe the effects of three types of dairy products (uht milk, cheese and butter) produced from milk derived from cows fed withhigh-oleic sunflower oil, on cvd risk biomarkers and plasma total cholesterol levels in adults with an increased risk of developing cvd. the aim is to determine whether an isoenergetic exchange of dairy products will affect vascular function and cvd biomarkers.


Eligibility criteria:
inclusion criteria: * mildly hypercholesterolemic: tc \<5.2 and \<8mmol/l * age: 25-70 * bmi: 19-32 kg/m2 * haemoglobin: \>125g/l for women and 135g/l for men * normal liver and kidney function exclusion criteria: * milk, cheese, butter, lactose allergy * drug treatment for hyperlipidaemia, hypertension, inflammation and hypercoagulation * suffered myocardial infarction/stroke in the past 12months * diabetic (diagnosed or fasting glucose \> 7 mmol/l) or suffer from other endocrine disorders * surgery in the previous 6 months * excessive alcohol consumption (\>28 unit/wk man; \>21 unit/wk women) * taking vitamin, mineral or fatty acid supplements (e.g. fish oil, calcium) * pregnant, lactating, planning a pregnancy or not using effective contraceptive precautions * smokers * vegans * anaemic * planning or on a weight reduction scheme * parallel participation in another intervention study * participating in intensive aerobic activity for \> 20 minutes 3 times per week * use of anti-inflammatory medication

Keywords: milk fatty acids total cholesterol vascular function blood pressure
a pilot study of high-dose omega-3 (soloways ™) polyunsaturated fatty acids in patients with dyslipidemia carrying fads1/fads2 variants

Conditions: Dyslipidemia

Summary: this pilot, genotype-stratified clinical trial aims to evaluate the safety and preliminary efficacy of high-dose omega-3 pufa supplementation in patients with dyslipidemia who carry a specific "unfavorable" genetic variant in the fads1/fads2 gene cluster. the study will compare lipid profile improvements and inflammatory markers between two cohorts: (1) homozygous (or high- risk) carriers of the fads1/fads2 variants and (2) non-carriers (wild-type). investigators hypothesize that individuals with these variants will show a more pronounced reduction in triglyceride levels and inflammatory markers following high-dose omega-3 supplementation due to their diminished endogenous synthesis of long-chain pufas.

dyslipidemia is a key risk factor for cardiovascular disease, often characterized by elevated triglycerides, low hdl cholesterol, and/or high ldl cholesterol. genetic variants in the fatty acid desaturase genes fads1 and fads2 can alter the conversion of shorter-chain polyunsaturated fatty acids into longer-chain forms (epa, dha), leading to suboptimal endogenous production of these beneficial fatty acids. omega-3 supplements, especially epa and dha, have been shown to lower triglycerides and modulate inflammatory pathways. this study examines whether high-dose omega-3 supplementation (2-4 g/day) confers greater benefit for carriers of certain "unfavorable" fads1/ fads2 polymorphisms, potentially optimizing cardiovascular risk reduction in this genetically defined subgroup.

Eligibility criteria:
inclusion criteria: * adults aged 18-75 years with documented dyslipidemia (elevated triglycerides and/or ldl cholesterol). * on stable lipid-lowering therapy (e.g., statins) or lifestyle regimen for at least 4 weeks prior to enrollment, if applicable. * willingness to undergo genetic testing for fads1/fads2 variants. for the fads variant cohort: confirmed homozygous (or high-risk) polymorphisms in fads1/fads2. * for the non-variant cohort: confirmed wild-type fads genotype. exclusion criteria: * use of prescription omega-3 products or high-dose fish oil supplements within 4 weeks prior to enrollment. * known hypersensitivity to fish or fish oil products. significant renal or hepatic impairment, uncontrolled thyroid disease, or other comorbidities that may confound results. * pregnancy or breastfeeding. * inability or unwillingness to comply with study procedures.

Keywords: genetics supplements omega3 fads1/fads2 gene cholesterol
biliary excretion of conjugated bile acids in humans measured by 11c-cholylsarcosine pet/ct

Conditions: Cholestasis; Primary Sclerosing Cholangitis; Primary Biliary Cirrhosis

Summary: we wish to develop a protocol for pet/ct examination of humans using the bile acid tracer 11c-cholylsarcosine. this is done by a series of pet/ct examinations of healthy humans and patients with cholestatic disorders.

the purpose of the study is the development of pet/ct protocols using 11c-csar for human use. pet/ct methods developed in the pig studies are translated to studies in healthy humans and patients with cholestatic disorders. dynamic pet/ct scans of the liver and biliary system are combined with measurements of tracer concentrations in a radial artery and a liver vein and measurements of hepatic blood flow by intravenous infusion of indocyanine green (icg)/ficks principle. kinetic parameters from pet/ct measurements and invasive measurements are compared for validation of the pet estimated parameters and refinement of the pet modeling, if required.

Eligibility criteria:
inclusion criteria: * patients with cholestatic disorders and healthy subjects exclusion criteria: * body weight above 110 kg (catheterization problematic). * diabetes * pregnant or breast feeding women.
determining the relationship between gut microbiota and immune response to influenza or covid-19 vaccine

Conditions: Inflammatory Bowel Diseases

Summary: this study will evaluate the effect of the microorganisms in the gut on how well the flu or covid-19 vaccine works in people who have a weakened immune system due to inflammatory bowel disease. participants can expect to be in the study for up to 65 days.

the overall objective of this study is to evaluate the role of gut microbiome in influenza or covid-19 vaccine response in immunosuppressed populations. microbial diversity (alpha diversity) is decreased in immunosuppressed patients and might be associated with lower immunogenicity to vaccines. it is known that patients with ibd have dysbiosis of their gut microbiome and those immunosuppressed may have a lower vaccine response. in this aim, the investigators will evaluate whether differences in microbial diversity predict immune response to the influenza and covid-19 vaccine. in this prospective study, immunosuppressed ibd patients will be vaccinated per standard of care and blood will be collected to measure the immune response. a fecal and saliva sample will be collected to characterize the gut microbiome. the investigators hypothesize that reduced richness / alpha-diversity in gut microbiota will correlate with those with a blunted vaccine response.

Eligibility criteria:
inclusion criteria: * a history of chronic (greater than 3 month) ulcerative colitis or crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic, and histopathologic criteria * currently one of the following groups: 1. group a: anti-tnf therapy group * maintenance monotherapy: infliximab (at least every 8 weeks), golimumab (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly) * combination therapy: anti-tnf combination therapy group on anti-tnf therapy as described above along with either methotrexate, azathioprine, or 6mp 2. group b: non-tng biologic * ustekinumab therapy: on either ustekinumab monotherapy or combination therapy with methotrexate, azathioprine, or 6mp * vedolizumab therapy: on either vedolizumab monotherapy or combination therapy with methotrexate, azathioprine, or 6mp * risankizumab therapy: 360mg at least every 8 weeks 3. group c: janus kinase therapy * tofacitinib therapy: at least 5mg po bid * upadactinib therapy: at least 15mg po daily * patient has been on stable treatment for ibd for at least three months * must be able to provide research samples between 28-65 days post influenza or covid-19 vaccination. exclusion criteria: * member of a vulnerable group (pregnant, lacking consent capacity, non-english speaking) * recent oral antibiotics within previous 2 months

Keywords: crohn's disease ulcerative colitis